2-Imidazolidinone Pharma Grade API, molecular mass 86.09 g/mol and melting range 131–135 °C, is introduced into direct compression tablet manufacture when a low-mass-fraction unit formula is required and the drug substance must be converted into an immediate-release oral solid without exposure to moisture. The formulation addition ratio for direct compression is 2.0–10.0% w/w of the final core mass, with the API controlled to a D90 below 200 µm; above 10.0% w/w, segregation potential increases unless the API is first co-milled with microcrystalline cellulose or pregelatinized starch. The downstream production process screens the crystalline API through a 0.5–0.7 mm oscillating sieve and combines it with spray-dried lactose, microcrystalline cellulose, and crospovidone in a bin blender rotating at 10–15 rpm for 10–15 min. Blend uniformity samples are withdrawn from 10–12 locations at 5, 10, and 15 min; the acceptance criterion is a coefficient of variation no greater than 5.0% for the API assay. Magnesium stearate is added at 0.25–0.5% w/w and blended for only 3 min, because prolonged lubrication lowers tablet tensile strength through hydrophobic film formation on the 2-imidazolidinone particles. Compression is performed on a rotary tablet press with precompression rollers set at 5–8 kN and main compression at 12–20 kN, targeting hardness of 6.0–9.0 kp for a 150–200 mg core, friability ≤0.8%, and disintegration ≤15 min. Because the compound is hygroscopic, the compression suite is maintained at 40–50% RH; batch records from manufacturing lines indicate that relative humidity above 60% increases tablet sticking and picking, requiring punch polishing or the addition of 0.1–0.3% w/w colloidal silicon dioxide. The terminal finished dosage type is an immediate-release uncoated or film-coated tablet. Release testing is conducted under USP <905> for uniformity of dosage units, USP <711> for dissolution in 900 mL of 0.1 N hydrochloric acid at 50 rpm, USP <701> for disintegration, and USP <921> for water content. Residual solvents are controlled according to ICH Q3C, elemental impurities according to ICH Q3D Option 1, and current good manufacturing practice under 21 CFR 210 and 211. No harmonized USP or Ph. Eur. monograph exists for 2-imidazolidinone as an API; therefore specification limits for assay and related substances are derived from ICH Q6A and validated against internal reference standards.

Why Does High-Shear Wet Granulation Require Viscosity Control of Binder Solutions?

When the direct compression blend fails flow or content uniformity criteria at a higher API addition ratio, high-shear wet granulation is selected to convert the drug substance into denser, free-flowing granules. The formulation addition ratio in this route is 8.0–20.0% w/w API on the dry granule basis, with lactose monohydrate and microcrystalline cellulose forming the main diluent fraction and croscarmellose sodium incorporated at 2.0–4.0% w/w as an intragranular disintegrant. The granulation train includes a high-shear granulator with a 300–600 L bowl; dry mixing proceeds for 2–3 min at impeller 150–200 rpm and chopper 1500 rpm. An aqueous hypromellose E5 binder solution at 3.0–5.0% w/w solids is sprayed into the moving powder mass at 4.0–8.0% w/w of the dry charge. Binder viscosity must be controlled within 4–10 mPa·s because lower viscosity produces weak granules and higher viscosity causes uneven liquid distribution, which is the main source of batch-to-batch granule density variability. The wet massing endpoint is determined by main motor power rise of 8–12% over the dry-mix baseline or by 60–120 s after binder addition, whichever is reached first. The wet mass is passed through a 4.0 mm rough mill and dried in a fluid-bed dryer with inlet air at 60–70 °C and product temperature not exceeding 45 °C; the API melting range is 131–135 °C, but case hardening of the excipient surfaces occurs if the drying temperature is raised too early. Drying continues until loss on drying is 1.5–2.5% w/w, and dried granules are milled through a 0.8–1.25 mm screen to a target D50 of 250–400 µm. The terminal dosage forms are film-coated tablets and hard gelatin or HPMC capsules filled from the dried granules. Compliance is established through USP <905> for content uniformity, USP <711> for dissolution, USP <921> for moisture, ICH Q3C for residual solvent control if isopropyl alcohol is used in the binder, and 21 CFR 211.80 through 211.94 for component control and equipment design. Production-line batch records show that granule particle-size distribution shifts when binder solution viscosity is not controlled, leading to tablet hardness variation outside ±10% of target.

Roller Compaction Produces Dense Ribbons That Control Fines

Roller compaction becomes the preferred dry granulation route when the API is physically incompatible with aqueous binder systems or when the formulation requires a higher addition ratio without the segregation risks of direct compression. The formulation addition ratio in roller compaction is 15.0–30.0% w/w API in the dry powder feed; the feed blend also contains microcrystalline cellulose, lactose monohydrate, crospovidone, and 0.5% w/w magnesium stearate in the external phase. The downstream production process uses a roller compactor with smooth or ribbed rolls operating at roll pressures of 5–10 kN/cm, roll gaps of 1.5–2.5 mm, and roll speeds of 5–15 rpm. Target ribbon density is 1.10–1.30 g/cm³; ribbons with density below 1.05 g/cm³ generate excessive fines after milling, while ribbons above 1.35 g/cm³ reduce granule compressibility and increase tablet capping. Milling is performed through a 0.8–1.25 mm screen with rotor speed set to limit fines below 150 µm to ≤35% of the granulation. Excessive fines raise the blend compressibility index above 25% and reduce tablet hardness; insufficient fines lower content uniformity because the API fraction may be concentrated in coarse granules. The terminal finished dosage forms consist of oral granules for sachets, tablets, and capsules after final blending with extragranular disintegrant at 2.0–4.0% w/w and magnesium stearate at 0.5% w/w. Compliance standards include USP <905> for content uniformity of sachets and tablets, USP <711> for dissolution, USP <921> for water content, and 21 CFR 211.110 for in-process control of granule density and particle size. The addition ratio and processing window are established through design of experiments; published data for this specific configuration is limited, so pilot-scale confirmation is required before scaling to production batches exceeding 500 kg.

When Capsule Filling Equipment Changes Powder Plug Compression Force

For hard-shell capsule manufacture with 2-Imidazolidinone Pharma Grade API, the unit operation is selected when the dosage strength demands a unit dose that cannot be compressed into an acceptable tablet size or when clinical protocols require encapsulation to avoid compaction-related degradation. The formulation addition ratio in the final capsule fill mass is 5.0–25.0% w/w, with the API preblended with lubricated granules or direct-fill excipients such as pregelatinized starch, microcrystalline cellulose, and dibasic calcium phosphate. In capsule filling, the powder blend is passed through a conical mill fitted with a 0.8 mm screen and then loaded into a tamping-pin encapsulator. Fill plug length is set to 4–6 mm, tamping stroke to 12–18 mm, and compression force to 20–40 N, depending on capsule size and fill weight. Fill weight is monitored gravimetrically at 10–20 min intervals, with acceptance limits of ±3% relative standard deviation across the run; capsule sizes 2 and 3 are typically used for fill masses of 100–180 mg. The product is released as hard gelatin or HPMC two-piece capsules for oral administration. Compliance standards include USP <905> for content uniformity, USP <711> for dissolution with 0.1 N hydrochloric acid, USP <921> for water content, and 21 CFR 211.113 for microbiological control of non-sterile oral solid dosage forms. ICH Q3D elemental impurity limits and ICH Q3C residual solvent limits are applied to the final capsule. Batch-to-batch variance in fill plug hardness is the main processing bottleneck when the powder mixture contains more than 0.5% w/w magnesium stearate or when the API particle shape is predominantly platy, requiring flow aids such as 0.1–0.3% w/w colloidal silicon dioxide.

Injectable Solution and Hydrolytic Stability Boundaries

Injectable solution manufacturing dissolves 2-Imidazolidinone Pharma Grade API in Water for Injection at a concentration range of 1.0–25.0 mg/mL, with the upper addition ratio determined by the selected buffer system and the need to maintain isotonicity rather than by the API’s aqueous solubility. The downstream production process begins with dissolution at 20–25 °C in a stainless-steel jacketed vessel under nitrogen overlay; the solution pH is adjusted to 5.0–7.0 using citrate or phosphate buffer at 10–50 mM ionic strength. Outside this pH range the cyclic urea structure may undergo hydrolytic ring-opening, and published data for the resulting degradation kinetics is limited; therefore pH excursion is treated as a critical process deviation. The bulk solution is filtered through a 0.45 µm prefilter and a 0.22 µm polyethersulfone final filter, filled into Type I borosilicate glass vials under ISO 14644-1 Class 5 conditions, and sealed with elastomeric closures. Terminal sterilization is performed by steam autoclaving at 121 °C for 15 min, with a target F0 of 8–15 min and load probes placed in the coldest vial locations. If forced degradation data show that the product exceeds the ICH Q3B identification threshold at F0 15 min, aseptic filtration without terminal steam sterilization is used instead. The terminal finished dosage type is a ready-to-use injectable solution or an intravenous infusion concentrate after dilution in 0.9% sodium chloride injection. Compliance standards include USP <790> for visible particulates, USP <788> for subvisible particulate matter, USP <1211> for sterility assurance, USP <85> for bacterial endotoxins, ICH Q3B for degradation products, ICH Q3D for elemental impurities, and 21 CFR 210 and 211 for aseptic processing and terminal sterilization. The filtration and filling train must be validated to maintain differential pressure below the filter bubble point, and filter integrity testing is performed before and after the filling operation.

Where long-term aqueous stability data are insufficient for liquid vials, the sterile drug product is processed as a lyophilized powder for reconstitution. The formulation addition ratio before lyophilization is 10–50 mg/mL total solids, with mannitol at 4.0–6.0% w/v as a crystallizing bulking agent and the API representing 20–40% w/w of the final dried cake; the remaining mass is contributed by buffer salts and, if needed, a cryoprotectant. The downstream production process begins with sterile filtration of the bulk solution through a 0.22 µm membrane into depyrogenated Type I glass vials; the vials are partially stoppered and loaded onto lyophilizer shelves. Shelf temperature is ramped at 0.5 °C/min to −40 °C and held for 2–4 h to ensure complete crystallization of the bulking agent, then primary drying is performed at shelf −20 °C to −10 °C and chamber pressure 50–100 µbar for 24–48 h, depending on cake height and vial fill depth. Secondary drying is carried out at shelf 25 °C for 6–10 h until the moisture content is ≤1.0% w/w; the terminal product is a sterile lyophilized plug in a single-dose vial for reconstitution with 10–20 mL Water for Injection before intramuscular or intravenous administration. Compliance standards include USP <921> for water content, USP <788> for particulate matter after reconstitution, USP <85> for bacterial endotoxins, USP <1211> for sterility assurance, ICH Q1A for stability testing, and 21 CFR 211.94 for container-closure systems. Because the collapse temperature of this specific formulation is not reported in public monographs, freeze-dry microscopy and differential scanning calorimetry are used before scale-up; published data for this specific configuration is limited, and pilot lyophilization runs with product temperature probes are required to establish the primary drying endpoint.